Phase 4 Completed N=74 Treatment

Fall Prevention in Older Adults With OAB

Overactive Bladder

Source: ClinicalTrials.gov NCT03946124 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2019

Primary outcomePrimary: Measure of Physical Activity — 1634.19 steps per day

◆ Published Evidence

Emerging

5citations · ~1 / year

Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive Bladder.

Female pelvic medicine & reconstructive surgery · 2021 · Likely link

Full text ↗ PubMed 34807883 ↗

Summary

Though OAB treatment may improve physical activity, there is a lack of easily administered instruments for measuring physical activity in older adults. Aim is to validate instruments to measure physical activity and preference for medication, and to determine the effect of preference for anti-cholinergic medication on adherence, physical activity, and falls risk. It's plan a prospective cohort study of adults aged 65 or older with OAB undergoing treatment with anti-cholinergic medication.

Linked Publications

Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive Bladder.

Female pelvic medicine & reconstructive surgery · 2021 · 5 citations · Likely link

Full text ↗PubMed 34807883 ↗

Outcome Measures

Outcome	Result	p-value
PRIMARY Measure of Physical Activity	1634.19	—

Eligibility Criteria

Inclusion Criteria

adults aged 65 or older, urinary urgency of quite a bit severity or more on the Overactive Bladder Questionnaire-Short Form (OABq-SF), eligible for pharmacologic therapy for overactive bladder

Exclusion Criteria

predominant stress incontinence (on UDI-6), current/recent use (6 m) or contraindication to anti-cholinergic medication, severe voiding difficulties, men on 5-alpha reductase inhibitors, severe neurologic disease, recent anti-incontinence or prolapse surgery, other urinary tract conditions such as calculus or recurrent UTI.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03946124) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.